Neboglamine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Neboglamine
Neboglamine.svg
Clinical data
Synonyms Nebostinel; N-(4,4-Dimethylcyclohexyl)-L-α-glutamine
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard 100.162.081 Edit this at Wikidata
Chemical and physical data
Formula C13H24N2O3
Molar mass 256.34126 g/mol
3D model (JSmol)

Neboglamine (INN) (developmental code names CR-2249, XY-2401), formerly known as nebostinel, is a positive allosteric modulator of the glycine site of the NMDA receptor which is under investigation for Rottapharm for the treatment of schizophrenia and cocaine dependence.[1][2][3][4][5][6] It shows cognition- and memory-enhancing effects in animal models.[7][8][9] As of June 2015, it is in phase II clinical trials for both schizophrenia and cocaine abuse.[10]

See also[edit]

References[edit]

  1. ^ Chiusaroli, Riccardo; Garofalo, Paolo; Espinoza, Stefano; Neri, Elisa; Caselli, Gianfranco; Lanza, Marco (2010). "Antipsychotic-like effects of the N-methyl-d-aspartate receptor modulator neboglamine: An immunohistochemical and behavioural study in the rat". Pharmacological Research. 61 (5): 430–436. doi:10.1016/j.phrs.2009.12.010. ISSN 1043-6618. 
  2. ^ Kantrowitz, Joshua; Javitt, Daniel C. (2012). "Glutamatergic transmission in schizophrenia". Current Opinion in Psychiatry: 1. doi:10.1097/YCO.0b013e32835035b2. ISSN 0951-7367. PMC 5224527Freely accessible. 
  3. ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. 
  4. ^ Santangelo, Rose M; Acker, Timothy M; Zimmerman, Sommer S; Katzman, Brooke M; Strong, Katie L; Traynelis, Stephen F; Liotta, Dennis C (2012). "Novel NMDA receptor modulators: an update". Expert Opinion on Therapeutic Patents. 22 (11): 1337–1352. doi:10.1517/13543776.2012.728587. ISSN 1354-3776. PMC 3677696Freely accessible. 
  5. ^ Zink, Mathias; Correll, Christoph U (2015). "Glutamatergic agents for schizophrenia: current evidence and perspectives". Expert Review of Clinical Pharmacology. 8 (3): 335–352. doi:10.1586/17512433.2015.1040393. ISSN 1751-2433. 
  6. ^ Köster, Luisa-Sophie; Carbon, Maren; Correll, Christoph U (2014). "Emerging drugs for schizophrenia: an update". Expert Opinion on Emerging Drugs. 19 (4): 511–531. doi:10.1517/14728214.2014.958148. ISSN 1472-8214. 
  7. ^ Garofalo, Paolo; Colombo, Silvia; Lanza, Marco; Revel, Laura; Makovec, Francesco (1996). "CR 2249: a New Putative Memory Enhancer. Behavioural Studies on Learning and Memory in Rats and Mice". Journal of Pharmacy and Pharmacology. 48 (12): 1290–1297. doi:10.1111/j.2042-7158.1996.tb03938.x. ISSN 0022-3573. 
  8. ^ Lanza, M.; Bonnafous, C.; Colombo, S.; Revel, L.; Makovec, F. (1997). "Characterization of a novel putative cognition enhancer mediating facilitation of glycine effect on strychnine-resistant sites coupled to NMDA receptor complex". Neuropharmacology. 36 (8): 1057–1064. doi:10.1016/S0028-3908(97)00092-0. ISSN 0028-3908. 
  9. ^ Lanza, Marco; Makovec, Francesco (1997). "Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator". CNS Drug Reviews. 3 (3): 245–259. doi:10.1111/j.1527-3458.1997.tb00326.x. ISSN 1080-563X. 
  10. ^ AdisInsight. "Neboglamine". Retrieved 2015-06-10. 

External links[edit]